Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23523770 | 0.85 | S1PR1 (0.43) | S1PR1S1PR3NPC1RAB9AKDM4E | |
| SCHEMBL30355450 | 0.85 | S1PR1 (0.43) | S1PR1S1PR3NPC1RAB9AKDM4E | |
| SCHEMBL30355633 | 0.79 | S1PR1 (0.43) | S1PR1S1PR3NPC1RAB9AKDM4E | |
| SCHEMBL23524055 | 0.79 | NPC1 (0.48) | S1PR1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30355601 | 0.79 | NPC1 (0.48) | S1PR1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL23524344 | 0.79 | S1PR1 (0.43) | S1PR1S1PR3NPC1RAB9AKDM4E | |
| SCHEMBL23523818 | 0.77 | S1PR1 (0.42) | S1PR1S1PR3NPC1RAB9AKDM4E | |
| SCHEMBL23523735 | 0.74 | GRM5 (0.55) | S1PR1S1PR3NPC1RAB9ATSHR | |
| SCHEMBL23524305 | 0.73 | GRM5 (0.36) | S1PR1S1PR3NPC1RAB9A | |
| SCHEMBL23523967 | 0.72 | GRM5 (0.58) | S1PR1S1PR3NPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885NPC1 301/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885NPC1 311/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885NPC1 301/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885NPC1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.